Today's Top Stories Also Noted: Spotlight On... CHS, GLG to relocate in Florida More Fierce Life Sciences News Today's Top News1. Emergent buys Trubion for up to $135M
Emergent BioSolutions is buying Trubion Pharmaceuticals for $96.8 million up front and up to $38.7 million of success-based milestones. Emergent gains Trubion's two clinical-stage product candidates for oncology and autoimmunity. The company also gains Trubion's two platforms--Small Modular Immunopharmaceutic (SMIPTM) and SCORPIONTM technologies--which could help develop additional drugs. Emergent will maintain research facilities in Seattle, WA, where Trubion is currently located. The buyout is part of Emergent's plan to move beyond biodefense work into other therapeutic areas. Trubion's pipeline includes:
"This acquisition strengthens Emergent's biologics capabilities in two key aspects," explained Emergent CEO Fuad El-Hibri. "First, it diversifies our product pipeline beyond infectious diseases into the two high growth areas of oncology and autoimmunity. And, second, it broadens our monoclonal antibody therapeutic capabilities." - here's Emergent's release Related Articles: Read more about: Trubion Pharmaceuticals, Emergent BioSolutions
2. GSK orders Sirtris execs to stop selling resveratrol
GlaxoSmithKline (NYSE: GSK) has ordered two Sirtris executives--Christoph Westphal and Michelle Dipp--to stop selling a resveratrol dietary supplement based on the drug the two companies have in development. In 2008, GSK forked over $720 million for access to Sirtris' pipeline of drugs based on resveratrol, a compound found in red wine that's thought to increase longevity. Many consumers have been clamoring for access to resveratrol following news reports touting its anti-aging effects. Westphal and Dipp have been selling the supplement through a nonprofit venture called Healthy Lifespan Institute. They charge $540 for a year's supply of the drug, but don't see any profit from sales. The supplement is a version of the experimental drug SRT501 that is in trials for Type 2 diabetes, cancer and other diseases. According to Xconomy, the Healthy Lifespan Institute's carefully worded site doesn't endorse the chemical. Dipp says they provide a safe, high-quality product that meets higher standards than other resveratrol supplements on the market. Not surprisingly, GSK isn't at all pleased with Westphal and Dipp's side business. Although their version of resveratrol is different from what GSK is developing, TheStreet says it could still undermine the major investment GSK made in buying Sirtris. The drug giant told Westphal and Dipp to halt sales of their supplement after Xconomy's report revealed their activities. GSK "was not aware that the Healthy Lifespan Institute was selling a resveratrol formulation on the Internet," according to a GSK statement obtained by TheStreet. "The company has instructed the GSK employees to cease their association with this activity and Michelle Dipp and Christoph Westphal will be resigning their positions on the board of Healthy Lifespan." There's no word yet on whether or not the two former Sirtris execs plan to follow GSK's orders. - read TheStreet report Related Articles: Read more about: Sirtris Pharmaceuticals, resveratrol, GlaxoSmithKline 3. Data-sharing breeds Alzheimer's progress
A 2003 venture to bring together the NIH, FDA, industry, universities and nonprofits is paying dividends for Alzheimer's biomarker research. There have been advancements in using imaging for early disease detection, and about 100 clinical studies are in progress for Alzheimer's. The Alzheimer's Disease Neuroimaging Initiative, as it is called, doesn't just raise money or conduct trials: one of the major goals when the group first set out in 2003 was to share information. All data on the projects is shared immediately, and anyone with a computer can access the information. No one company will benefit from the data. "It's not science the way most of us have practiced it in our careers," University of Pennsylvania Alzheimer's researcher Dr. John Trojanowski tells the New York Times. "But we all realized that we would never get biomarkers unless all of us parked our egos and intellectual-property noses outside the door and agreed that all of our data would be public immediately." By pooling data, the foundation has achieved far more than the industry could have done alone. And there's hope that this approach to Alzheimer's research will serve as a template for other diseases--like Parkinson's--that have stumped researchers. The Michael J. Fox foundation has already poured $40 million into a Parkinson's biomarkers project that is set to enroll U.S. and European patients. - here's the New York Times report Related Articles: Read more about: biomarkers, Alzheimer's 4. CeNeRx raises $13M as it preps for Phase II
Research Triangle Park-based CeNeRx BioPharma has raised $13 million to conduct Phase II trials of its experimental antidepressant. Perseus Soros Biopharmaceutical Fund, L Capital Partners and Pappas Ventures all participated in the Series C round. CeNeRx is preparing to start a Phase II trial TriRima, the company's lead drug for treatment-resistant depression. "These funds will support the Phase II trial of TriRima as monotherapy for treatment-resistant depression," says CeNeRx CEO Barry Brand. "We are pleased with the continuing confidence and support of our investors and look forward to advancing the CeNeRx pipeline." - check out the release from CeNeRx Related Articles: Read more about: CeNeRx BioPharma, Biotech Venture Capital 5. Epitomics spins off mAb company Apexigen
Burlingame, CA-based Epitomics has spun off a new biotech called Apexigen, which will focus on developing humanized monoclonal antibodies for treatment of cancer and immuno-disorders. Apexigen was formed with exclusive rights to develop and commercialize therapeutic monoclonal antibodies derived from Epitomics' rabbit monoclonal antibody technology and the mutational lineage guided humanization technology. The company will use the technologies to develop therapies for both humans and animals. Xiaodong Yang has been appointed as president and CEO of the new company. An agreement with Epitomics gives Apexigen full access to the company's antibody generation and screening infrastructure. "We believe that an independent company with experience, expertise and focused pharmaceutical product development offers the best opportunity to see technology developed at Epitomics have a direct therapeutic impact on peoples' lives," says Guo-Liang Yu, president & CEO of Epitomics. "Epitomics will continue to focus on its core business and assist Apexigen as it develops therapeutics to treat serious diseases." - check out the Epitomics release Read more about: spin-off, Epitomics, Apexigen Also NotedSPOTLIGHT ON... CHS, GLG to relocate in Florida Two small biotechs hoping to create cancer drugs will move to Jupiter, Florida. CHS Pharma is moving four employees from Miami-Dade County and plans to hire 25 workers over the next five years. GLG Pharma is moving from Tampa to the Alexandria Innovation Center, where it plans to hire four people. Report
> Inspire Pharmaceuticals has entered into an executive employment agreement with Charles Johnson, who will become executive VP of R&D and CMO, effective Sept. 15. Inspire release > Tuomo Pätsi has joined Human Genome Sciences as VP, HGS Europe. Pätsi, formerly regional VP, Northern Europe at Celgene International, will be responsible for European sales, marketing and medical affairs. HGS release > The town of Oro Valley has found a winning formula for bringing high-tech, high-pay jobs home: be responsive to businesses and they will come. Innovation Park is the technological hotbed of Oro Valley. In the last decade, it has grown from 565 acres of empty desert, into the industrial home for much of Southern Arizona's biotech industry. Story > Mission Bay is adding another VC. Life sciences venture capital firm Third Rock Ventures, based in Boston, will set up shop in San Francisco's Mission Bay biotech enclave. Third Rock principal Jake Bauer and a partner will move to San Francisco, according to the Boston Globe's Boston.com, and the firm will hire a new partner. News > OriGene Technologies, a gene-centric life sciences company, has announced the acquisition of Blue Heron Biotechnology, a pioneer in the gene synthesis business since 1999. OriGene release > PharmAthene has reported financial and operational results for the second quarter and six months that ended June 30. The company saw a decline in revenue compared with the same periods last year due to the completion in the third quarter of 2009 of the first phase of development activities under the company's contract with the DoD for Protexia. PharmaAthene release And Finally... Cannabis Science has executed a joint venture agreement with Smokefree Innotec. The objective of the joint venture is to develop and market several high-tech smoke-free vaporized medical cannabis pharmaceutical products. Both parties equally share in the revenues derived from this JV. Cannabis Science release
> Abandoning propofol, Teva lays off 70. Article > Lilly shares slide on second big patent setback. Report > Genomics might have rescued Sanofi diet drug. News > FDA: GSK seizure drug linked to meningitis. Item > What if doctor dinners were illegal? Story
©2010 FierceMarkets Manage Your Subscription Contact Us Editor-in-Chief: John Carroll. Editor: Maureen Martino. Publisher: Arsalan Arif. VP, Sales: Ryan Willumson. Advertise Advertising/Lead-Generation: Ryan Willumson. Request a media kit. Explore Our Network You may enjoy these publications from FierceMarkets: | |||||||||||||||||||||||||||||||||||||
@FierceBiotech: Ramius tempts Cypress shareholders with sweetened offer. 
This email was sent to beritanarablog@gmail.com as part of the FierceBiotech email list which is administered by 
REVIEW : Scarlett Body Cream dan Body Serum Juara Untuk Kulit Cantikmu
-
Hai, ketemu lagi di review aku kali ini tentang duo produk barunya
Scarlett yang pastinya menambah pilihan kamu untuk merawat kulit supaya
lebih sehat dan...